Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.

Liver international : official journal of the International Association for the Study of the Liver - 1 Aug 2006

Höroldt Barbara, Haydon Geoffrey, O'Donnell Katrina, Dudley Tracey, Nightingale Peter, Mutimer David

Abstract excerpt

BACKGROUND: The treatment of hepatitis C patients with advanced cirrhotic liver disease remains challenging and data on the outcome of treatment for this patient group is limited. RESULTS: Between September 2000 and August 2004, 61 cirrhotic patients started treatment with pegylated interferon and ribavirin (42 male, age range 29-69 years, 26 Asian). Forty-three (70%) patients were serum hepatitis C virus (HCV)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Tolerance

Share to Hepacivirus

Share to Hepatitis C

Share to Interferon Type I

Share to Ribavirin

Share to Safety

Source

Identifiers

PMID: 16842320
DOI: 10.1111/j.1478-3231.2006.01272.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.PMID 16842320Read ↗

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].Semantic proximity Read ↗

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.Semantic proximity Read ↗

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Antiviral treatment of chronic hepatitis C in clinical routine.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

[Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C].Semantic proximity Read ↗

Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.Semantic proximity Read ↗

Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.Semantic proximity Read ↗

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.Semantic proximity Read ↗

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.